Literature DB >> 22684773

Inhibition of autocrine IGF-II on effect of human HepG2 cell proliferation and angiogenesis factor expression.

Ninghua Yao1, Dengfu Yao, Li Wang, Zhizhen Dong, Wei Wu, Liwei Qiu, Xiaodi Yan, Dandan Yu, Jie Chen, Wenli Sai, Haijian Zhang, Junlin Yang.   

Abstract

Abnormal expression of insulin-like growth factor II (IGF-II) is associated with the hepatocyte malignant transformation and hepatocellular carcinoma (HCC) progress. In this study, specific IGF-II miRNA plasmids were constructed and transfected to HepG2 cells to knockdown IGF-II expression for observing effects on the cell proliferation, survival, apoptosis, angiogenesis, and anchorage-independent colony formation. IGF-II mRNA was evaluated by quantitative real-time polymerase chain reaction, and the level of IGF-II or vascular endothelial growth factor (VEGF) was quantitatively analyzed by ELISA. Our data shown that downregulation of IGF-II expression resulted in the viability alteration, proliferation inhibition, and apoptosis occurrence of HepG2 cells. The level of VEGF expression in the supernatant of HepG2 cells in the IGF-II-miRNA-transfected group was significantly decreasing (P < 0.01) than those in the untransfected group or the miRNA-neg-transfected group, with the susceptibility to anoikis and decreasing of anchorage-independent colony formation of HepG2 cells. Thus, we conclude that IGF-II is a potential molecular target for HCC gene therapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22684773     DOI: 10.1007/s13277-012-0436-x

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  30 in total

1.  Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy.

Authors:  Danielle B Ulanet; Dale L Ludwig; C Ronald Kahn; Douglas Hanahan
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-10       Impact factor: 11.205

2.  A vision for the future of genomics research.

Authors:  Francis S Collins; Eric D Green; Alan E Guttmacher; Mark S Guyer
Journal:  Nature       Date:  2003-04-14       Impact factor: 49.962

Review 3.  Dysregulation of growth factor signaling in human hepatocellular carcinoma.

Authors:  K Breuhahn; T Longerich; P Schirmacher
Journal:  Oncogene       Date:  2006-06-26       Impact factor: 9.867

4.  Targeting of bone-derived insulin-like growth factor-II by a human neutralizing antibody suppresses the growth of prostate cancer cells in a human bone environment.

Authors:  Taichi Kimura; Takeshi Kuwata; Satoshi Ashimine; Manabu Yamazaki; Chisako Yamauchi; Kanji Nagai; Akashi Ikehara; Yang Feng; Dimiter S Dimitrov; Seiichi Saito; Atsushi Ochiai
Journal:  Clin Cancer Res       Date:  2009-12-22       Impact factor: 12.531

Review 5.  The role of the insulin-like growth factor system in colorectal cancer: review of current knowledge.

Authors:  Rajaraman Durai; Wenxuan Yang; Sharmila Gupta; Alexander M Seifalian; Marc C Winslet
Journal:  Int J Colorectal Dis       Date:  2005-01-14       Impact factor: 2.571

6.  Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis.

Authors:  F Peruzzi; M Prisco; M Dews; P Salomoni; E Grassilli; G Romano; B Calabretta; R Baserga
Journal:  Mol Cell Biol       Date:  1999-10       Impact factor: 4.272

7.  Obesity, inflammatory signaling, and hepatocellular carcinoma-an enlarging link.

Authors:  Sara Toffanin; Scott L Friedman; Josep M Llovet
Journal:  Cancer Cell       Date:  2010-02-17       Impact factor: 31.743

8.  Characteristics of hepatic igf-ii expression and monitored levels of circulating igf-ii mRNA in metastasis of hepatocellular carcinoma.

Authors:  Jing Qian; Dengfu Yao; Zhizhen Dong; Wei Wu; Liwei Qiu; Ninghua Yao; Shanshan Li; Yinzhu Bian; Zhiwei Wang; Gongsheng Shi
Journal:  Am J Clin Pathol       Date:  2010-11       Impact factor: 2.493

9.  Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2'-O-methyl RNA, phosphorothioates and small interfering RNA.

Authors:  Arnold Grünweller; Eliza Wyszko; Birgit Bieber; Ricarda Jahnel; Volker A Erdmann; Jens Kurreck
Journal:  Nucleic Acids Res       Date:  2003-06-15       Impact factor: 16.971

Review 10.  Specific molecular markers in hepatocellular carcinoma.

Authors:  Deng-Fu Yao; Zhi-Zhen Dong; Min Yao
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2007-06
View more
  15 in total

1.  Glypican-3 as an emerging molecular target for hepatocellular carcinoma gene therapy.

Authors:  Min Yao; Li Wang; Zhizhen Dong; Qi Qian; Yun Shi; Dandan Yu; Shiye Wang; Wenjie Zheng; Dengfu Yao
Journal:  Tumour Biol       Date:  2014-03-16

2.  Expression of IMP3 and IGF2 in giant cell tumor of spine is associated with tumor recurrence and angiogenesis.

Authors:  K Zhang; M Zhou; H Chen; G Wu; K Chen; H Yang
Journal:  Clin Transl Oncol       Date:  2015-03-05       Impact factor: 3.405

3.  Abnormal expression of insulin-like growth factor-I receptor in hepatoma tissue and its inhibition to promote apoptosis of tumor cells.

Authors:  Zhizhen Dong; Min Yao; Li Wang; Xiaodi Yan; Xing Gu; Yun Shi; Ninghua Yao; Liwei Qiu; Wei Wu; Dengfu Yao
Journal:  Tumour Biol       Date:  2013-12

Review 4.  Encouraging specific biomarkers-based therapeutic strategies for hepatocellular carcinoma.

Authors:  Min Yao; Jun-Ling Yang; De-Feng Wang; Li Wang; Ying Chen; Deng-Fu Yao
Journal:  World J Clin Cases       Date:  2022-04-16       Impact factor: 1.534

5.  AU-binding factor 1 expression was correlated with metadherin expression and progression of hepatocellular carcinoma.

Authors:  Yingzhuo Yang; Peng Kang; Jie Gao; Chunlin Xu; Shimei Wang; Haiyu Jin; Yunling Li; Wenjuan Liu; Xia Wu
Journal:  Tumour Biol       Date:  2013-11-09

6.  Metformin sensitizes hepatocellular carcinoma to arsenic trioxide-induced apoptosis by downregulating Bcl2 expression.

Authors:  Xuejun Yang; Deguang Sun; Yu Tian; Sunbin Ling; Liming Wang
Journal:  Tumour Biol       Date:  2014-12-11

7.  IGF-I receptor as an emerging potential molecular-targeted for hepatocellular carcinoma in vitro and in vivo.

Authors:  Min Yao; Li Wang; Junling Yang; Xiaodi Yan; Yin Cai; Dengfu Yao
Journal:  Tumour Biol       Date:  2016-09-13

Review 8.  Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease?

Authors:  Antonella Scalera; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

9.  Astrocyte elevated gene-1 is a novel biomarker of epithelial-mesenchymal transition and progression of hepatocellular carcinoma in two China regions.

Authors:  Jiasheng Zheng; Cong Li; Xia Wu; Yingzhuo Yang; Meijun Hao; Shoupeng Sheng; Yu Sun; Honghai Zhang; Jiang Long; Caixia Hu
Journal:  Tumour Biol       Date:  2013-10-18

10.  Evaluation of Glypican-3 expression in benign and malignant salivary gland tumors.

Authors:  Azadeh Andisheh-Tadbir; Mohammad Javad Ashraf; Ali Gudarzi; Razieh Zare
Journal:  J Oral Biol Craniofac Res       Date:  2018-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.